MCID: TRM010
MIFTS: 56

Traumatic Brain Injury

Categories: Ear diseases, Neuronal diseases

Aliases & Classifications for Traumatic Brain Injury

MalaCards integrated aliases for Traumatic Brain Injury:

Name: Traumatic Brain Injury 39 55 44 3

Classifications:



Summaries for Traumatic Brain Injury

MedlinePlus : 44 Traumatic brain injury (TBI) happens when a bump, blow, jolt, or other head injury causes damage to the brain. Every year, millions of people in the U.S. suffer brain injuries. More than half are bad enough that people must go to the hospital. The worst injuries can lead to permanent brain damage or death. Half of all TBIs are from motor vehicle accidents. Military personnel in combat zones are also at risk. Symptoms of a TBI may not appear until days or weeks following the injury. A concussion is the mildest type. It can cause a headache or neck pain, nausea, ringing in the ears, dizziness, and tiredness. People with a moderate or severe TBI may have those, plus other symptoms: A headache that gets worse or does not go away Repeated vomiting or nausea Convulsions or seizures Inability to awaken from sleep Slurred speech Weakness or numbness in the arms and legs Dilated eye pupils Health care professionals use a neurological exam and imaging tests to assess TBI. Serious traumatic brain injuries need emergency treatment. Treatment and outcome depend on how severe the injury is. TBI can cause a wide range of changes affecting thinking, sensation, language, or emotions. TBI can be associated with post-traumatic stress disorder. People with severe injuries usually need rehabilitation. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Traumatic Brain Injury is related to head injury and persistent vegetative state. An important gene associated with Traumatic Brain Injury is APOE (Apolipoprotein E), and among its related pathways/superpathways are PAK Pathway and Nanog in Mammalian ESC Pluripotency. The drugs Mannitol and Midazolam have been mentioned in the context of this disorder. Affiliated tissues include Bone, brain and testes, and related phenotypes are Decreased viability with paclitaxel and Decreased viability with paclitaxel

CDC : 3 CDC defines a traumatic brain injury (TBI) as a disruption in the normal function of the brain that can be caused by a bump, blow, or jolt to the head, or penetrating head injury. Everyone is at risk for a TBI, especially children and older adults.

NINDS : 55 Traumatic brain injury (TBI), a form of acquired brain injury, occurs when a sudden trauma causes damage to the brain. TBI can result when the head suddenly and violently hits an object, or when an object pierces the skull and enters brain tissue.  Symptoms of a TBI can be mild, moderate, or severe, depending on the extent of the damage to the brain. A person with a mild TBI may remain conscious or may experience a loss of consciousness for a few seconds or minutes. Other symptoms of mild TBI include headache, confusion, lightheadedness, dizziness, blurred vision or tired eyes, ringing in the ears, bad taste in the mouth, fatigue or lethargy, a change in sleep patterns, behavioral or mood changes, and trouble with memory, concentration, attention, or thinking.  A person with a moderate or severe TBI may show these same symptoms, but may also have a headache that gets worse or does not go away, repeated vomiting or nausea, convulsions or seizures, an inability to awaken from sleep, dilation of one or both pupils of the eyes, slurred speech, weakness or numbness in the extremities, loss of coordination, and increased confusion, restlessness, or agitation.

Wikipedia : 77 Traumatic brain injury (TBI), also known as intracranial injury, occurs when an external force injures... more...

Related Diseases for Traumatic Brain Injury

Diseases related to Traumatic Brain Injury via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 404)
# Related Disease Score Top Affiliating Genes
1 head injury 33.2 APOE ENO2 S100B
2 persistent vegetative state 32.9 APOE ENO2
3 brain edema 31.3 AQP4 GFAP IL6
4 post-traumatic stress disorder 30.9 APOE BDNF COMT DRD2
5 spinal cord injury 30.7 AQP4 BDNF CASP3 GFAP IL6
6 substance abuse 30.5 BDNF COMT DRD2
7 alzheimer disease 30.4 APOE BDNF CASP3 GFAP S100B UCHL1
8 hydrocephalus 30.3 APOE ENO2 GFAP IGF1 MBP
9 mood disorder 30.3 BDNF COMT DRD2 IL6
10 stroke, ischemic 30.3 APOE AQP4 CASP3 ENO2 MBP
11 status epilepticus 30.2 BDNF CASP3 ENO2 GFAP
12 disease of mental health 30.2 APOE BDNF COMT DRD2 IL6
13 middle cerebral artery infarction 30.2 ENO2 S100B
14 psychotic disorder 30.1 BDNF COMT DRD2 S100B
15 neurilemmoma 30.1 ENO2 GFAP S100B
16 bacterial meningitis 30.1 IL10 IL6 S100B
17 chiari malformation 30.0 GFAP MBP
18 personality disorder 29.9 BDNF COMT DRD2
19 obsessive-compulsive disorder 29.9 BDNF COMT DRD2
20 neuroaxonal dystrophy 29.9 ENO2 IGF1 MBP
21 brain injury 29.8 APOE BDNF CASP3 COMT DRD2 ENO2
22 appendicitis 29.8 ENO2 IL10 IL6
23 polysubstance abuse 29.8 COMT DRD2
24 eating disorder 29.7 BDNF COMT DRD2
25 major depressive disorder 29.5 APOE BDNF COMT DRD2 IL6
26 brain cancer 29.4 AQP4 CASP3 ENO2 GFAP MBP
27 myocardial infarction 29.4 APOE CASP3 IL10 IL6 S100B
28 parkinson disease, late-onset 29.4 APOE BDNF CASP3 COMT DRD2 UCHL1
29 multiple sclerosis 29.1 APOE AQP4 BDNF GFAP IL10 IL6
30 osteoporosis 28.8 APOE GH1 IGF1 IL6
31 moderate and severe traumatic brain injury 12.6
32 locked-in syndrome 11.6
33 dementia pugilistica 11.5
34 dysphagia 11.5
35 pseudobulbar affect 11.5
36 shaken baby syndrome 11.5
37 post-traumatic epilepsy 11.5
38 cerebral atrophy 11.5
39 apraxia 11.5
40 agnosia 11.5
41 swallowing disorders 11.5
42 diarrhea 5, with tufting enteropathy, congenital 11.2
43 prosopagnosia 11.2
44 childhood apraxia of speech 11.2
45 non 24 hour sleep wake disorder 11.2
46 tremor 11.2
47 ocular motor apraxia 10.8
48 intracranial hypertension 10.8
49 hypopituitarism 10.7
50 depression 10.7

Graphical network of the top 20 diseases related to Traumatic Brain Injury:



Diseases related to Traumatic Brain Injury

Symptoms & Phenotypes for Traumatic Brain Injury

GenomeRNAi Phenotypes related to Traumatic Brain Injury according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 8.92 CASP3 IGF1 IL10
2 Decreased viability with paclitaxel GR00179-A-2 8.92 IGF1

MGI Mouse Phenotypes related to Traumatic Brain Injury:

47 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.4 APOE AQP4 BDNF CASP3 COMT DRD2
2 growth/size/body region MP:0005378 10.36 APOE AQP4 BDNF CASP3 DRD2 ENO2
3 cardiovascular system MP:0005385 10.32 APOE AQP4 CASP3 COMT DRD2 GFAP
4 cellular MP:0005384 10.32 APOE BDNF CASP3 DRD2 ENO2 GFAP
5 homeostasis/metabolism MP:0005376 10.32 APOE AQP4 BDNF CASP3 COMT DRD2
6 nervous system MP:0003631 10.25 APOE AQP4 BDNF CASP3 COMT DRD2
7 mortality/aging MP:0010768 10.23 APOE AQP4 BDNF CASP3 DRD2 GFAP
8 digestive/alimentary MP:0005381 10.22 APOE AQP4 BDNF CASP3 DRD2 GFAP
9 hematopoietic system MP:0005397 10.22 APOE AQP4 CASP3 COMT DRD2 IGF1
10 endocrine/exocrine gland MP:0005379 10.21 APOE AQP4 BDNF CASP3 COMT DRD2
11 immune system MP:0005387 10.19 APOE AQP4 CASP3 COMT DRD2 GFAP
12 integument MP:0010771 10.13 APOE BDNF CASP3 DRD2 IGF1 IL10
13 hearing/vestibular/ear MP:0005377 10.01 APOE AQP4 BDNF CASP3 IGF1 MBP
14 muscle MP:0005369 9.98 APOE CASP3 DRD2 GFAP IGF1 IL10
15 normal MP:0002873 9.97 BDNF DRD2 GFAP IGF1 IL10 MBP
16 renal/urinary system MP:0005367 9.92 APOE AQP4 CASP3 COMT DRD2 IGF1
17 reproductive system MP:0005389 9.91 APOE BDNF CASP3 COMT DRD2 IGF1
18 respiratory system MP:0005388 9.9 APOE AQP4 BDNF CASP3 COMT DRD2
19 taste/olfaction MP:0005394 9.35 APOE BDNF CASP3 DRD2 ENO2
20 vision/eye MP:0005391 9.23 APOE AQP4 BDNF CASP3 GFAP IL10

Drugs & Therapeutics for Traumatic Brain Injury

Drugs for Traumatic Brain Injury (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 468)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 69-65-8 6251 453
2
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 59467-70-8 4192
3
Morphine Approved, Investigational Phase 4,Phase 1,Phase 2 57-27-2 5288826
4
Zinc Approved, Investigational Phase 4 7440-66-6 32051
5
Citalopram Approved Phase 4,Phase 2,Not Applicable 59729-33-8 2771
6
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 62-31-7, 51-61-6 681
7
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 113-45-1 4158
8
Amantadine Approved Phase 4,Phase 2,Phase 3,Not Applicable 768-94-5 2130
9
Cisatracurium Approved Phase 4 96946-41-7
10
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
11
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
12
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
13
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
14
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
15
Tranexamic Acid Approved Phase 4,Phase 3,Phase 2 1197-18-8 5526
16
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
17
Norepinephrine Approved Phase 4,Phase 2,Not Applicable 51-41-2 439260
18
Testosterone Approved, Experimental, Investigational Phase 4,Phase 2,Not Applicable 58-22-0, 481-30-1 10204 6013
19
Enoxaparin Approved Phase 4,Phase 1 9005-49-6 772
20
Ethanol Approved Phase 4,Phase 3,Phase 2,Not Applicable 64-17-5 702
21
Sertraline Approved Phase 4,Phase 2,Phase 3,Not Applicable 79617-96-2 68617
22
Acetaminophen Approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 103-90-2 1983
23
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 99-66-1 3121
24
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-23-7 5754
25
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-03-3
26
Propranolol Approved, Investigational Phase 4,Phase 2,Phase 1 525-66-6 4946
27
Rivastigmine Approved, Investigational Phase 4,Phase 3 123441-03-2 77991
28
Methyltestosterone Approved Phase 4,Phase 2 58-18-4 6010
29
Testosterone undecanoate Approved, Investigational Phase 4,Phase 2 5949-44-0
30
Testosterone enanthate Approved Phase 4,Phase 2 315-37-7 9416
31
Dalteparin Approved Phase 4,Phase 3 9005-49-6
32
Heparin Approved, Investigational Phase 4,Phase 3 9005-49-6 46507594 772
33
Thiopental Approved, Vet_approved Phase 4,Phase 3 76-75-5 3000715
34
Topiramate Approved Phase 4,Early Phase 1 97240-79-4 5284627
35
Fosphenytoin Approved, Investigational Phase 4,Not Applicable 93390-81-9 56339
36
Levetiracetam Approved, Investigational Phase 4,Phase 3,Phase 2 102767-28-2 441341
37
Phenytoin Approved, Vet_approved Phase 4,Phase 2,Early Phase 1,Not Applicable 57-41-0 1775
38
Simvastatin Approved Phase 4 79902-63-9 54454
39
Tizanidine Approved, Investigational Phase 4,Phase 1 51322-75-9 5487
40
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 2 93-14-1 3516
41
Dextromethorphan Approved Phase 4,Phase 3,Phase 2 125-71-3 5362449 5360696
42
Quinidine Approved, Investigational Phase 4,Phase 2 56-54-2 441074
43
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 57-83-0 5994
44
Fluoxetine Approved, Vet_approved Phase 4,Not Applicable 54910-89-3 3386
45
Paroxetine Approved, Investigational Phase 4,Not Applicable 61869-08-7 43815
46
Prednisolone Approved, Vet_approved Phase 4,Phase 1,Phase 2 50-24-8 5755
47
Sumatriptan Approved, Investigational Phase 4,Phase 2 103628-46-2 5358
48
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 1,Phase 2 302-25-0
49
Memantine Approved, Investigational Phase 4,Not Applicable 19982-08-2 4054
50
Methylprednisolone hemisuccinate Approved Phase 4,Phase 1,Phase 2 2921-57-5

Interventional clinical trials:

(show top 50) (show all 1306)
# Name Status NCT ID Phase Drugs
1 Effect of Rozerem on Sleep Among People With Traumatic Brain Injury Unknown status NCT01207050 Phase 4 Ramelteon
2 A Clinical Trial of the Effect of Midazolam on the Cerebral Metabolism and Inflammatory Response in Patients With Moderate and Severe Traumatic Brain Injury Unknown status NCT02071407 Phase 4 Midazolam;Placebo
3 Intensive Versus Nonintensive Insulin Therapy for Hyperglycemia After Traumatic Brain Injury Unknown status NCT02161055 Phase 4 Insulin
4 Antidepressant Maintenance in Traumatic Brain Injury Unknown status NCT00162916 Phase 4 citalopram;Placebo
5 The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery Unknown status NCT01606111 Phase 4 Cerebrolysin;0.9% NaCl, saline
6 Methylphenidate for Attention Problems After Pediatric TBI Unknown status NCT01933217 Phase 4 Methylphenidate;Placebo
7 Amantadine for Treatment of Symptoms of the Post-Traumatic Confusional State Unknown status NCT00693121 Phase 4 Amantadine hydrochloride;Placebo capsule
8 Is Sensory Stimulation Effective in Reducing Time Spent in a Coma or Vegetative State Unknown status NCT00163878 Phase 4
9 Treatment of Intracranial Hypertension of Severe Tramatic Brain Injured Patients. Physiopathologic Effects of Neuromuscular Blocking Agents Unknown status NCT02404779 Phase 4 cisatracurium besilate
10 Normothermia in Patients With Acute Cerebral Damage Unknown status NCT00491192 Phase 4 Diclofenac
11 Does Discontinuation of Aspirin Treatment Following Head Trauma Decrease the Incidence of Chronic Subdural Hematoma? Unknown status NCT01470040 Phase 4 discontinuation of aspirin therapy;continuation of aspirin therapy
12 Intensive Insulin Therapy for Strict Glycemic Control in Neurosurgical Patients: Safety and Efficacy Unknown status NCT00505505 Phase 4 Insulin (Actrapid)
13 TXA in the EMS on the Helicopter and the Ambulance Unknown status NCT02354885 Phase 4 Tranexamic Acid
14 Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD) Unknown status NCT01517711 Phase 4 Tramadol;Placebo
15 Using Propranolol in Traumatic Brain Injury to Reduce Sympathetic Storm Phenomenon Completed NCT03401515 Phase 4 Propranolol Hydrochloride 1 MG/ML
16 An Extension Study Evaluating the Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury (TBI) With Persistent Cognitive Deficits Completed NCT00219245 Phase 4 Rivastigmine
17 Pharmacological Intervention in Depression After Traumatic Brain Injury Completed NCT00205491 Phase 4 Venlafaxine
18 The Relationship Between Traumatic Brain Injury and Dopamine (a Chemical in the Brain) Completed NCT02015949 Phase 4 Methylphenidate;Placebo
19 The Study of Cognitive Rehabilitation Effectiveness for Mild Traumatic Brain Injury Completed NCT01339806 Phase 4
20 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury Completed NCT00957671 Phase 4 Recombinant human growth hormone
21 Depression and Traumatic Brain Injury Completed NCT00254007 Phase 4 citalopram (celexa)
22 Pediatric Traumatic Brain Injury: Methylphenidate Effects on Early Recovery Completed NCT00035139 Phase 4 methylphenidate
23 Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy Completed NCT01201863 Phase 4 Androgel (Testosterone Gel);Androgel Placebo
24 Optimized Therapy in Severe Traumatic Brain Injured Patients Completed NCT02130674 Phase 4 Dipeptiven
25 Beta Blockade in in Traumatic Brain Injury Completed NCT02957331 Phase 4 Propranolol
26 The Use of Low Molecular Weight Heparin in Traumatic Brain Injury Completed NCT00170378 Phase 4 Enoxaparin
27 Bispectral Index Value Changes During Induction and Surgical Decompression in Head Injury Patients Completed NCT03480880 Phase 4
28 Topiramate Treatment of Hazardous and Harmful Alcohol Use in Veterans With TBI Completed NCT01750268 Phase 4 Topiramate;Placebo
29 Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention Completed NCT00618436 Phase 4 Levetiracetam;Phenytoin
30 Simvastatin for mTBI Completed NCT01952288 Phase 4 simvastatin;Placebo Oral Tablet
31 BOTOX® Versus Zanaflex® for the Treatment of Post-Stroke or Traumatic Brain Injury Upper Limb Spasticity Completed NCT00430196 Phase 4 BOTOX®;Zanaflex®
32 Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA) Completed NCT01799941 Phase 4 Nuedexta (DM 20 mg/Q 10 mg)
33 Enteral Glutamine in Neurologically-injured Patients Completed NCT00204971 Phase 4
34 Does Oral Micronized Progesterone Shorten Time of Symptoms From Concussion Completed NCT01809639 Phase 4 Progesterone;Placebo
35 NIMI-NICU: Non Invasive Monitoring of the Intracranial Pressure - NeuroIntensive Care Unit Completed NCT01685476 Phase 4
36 Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Practical Trial Completed NCT00680602 Phase 4 SSRI (fluoxetine, sertraline, paroxetine, citalopram)
37 Effect of IV Acetaminophen on Patients in the Neurocritical Care Unit Completed NCT01948505 Phase 4 Intravenous acetaminophen;Placebo for IV acetaminophen
38 Mannitol Versus Hypertonic Saline Solution in the Treatment of Elevated Intracranial Pressure Completed NCT00447018 Phase 4 20% mannitol;7.45% hypertonic saline solution
39 Does Short-Term Anti-Seizure Prophylaxis After Traumatic Brain Injury Decrease Seizure Rates? Recruiting NCT03054285 Phase 4 Levetiracetam
40 Effect of Amantadine Administration on Spatial Functioning Following Traumatic Brain Injury Recruiting NCT02321761 Phase 4 Amantadine hydrochloride
41 Prazosin and CSF Biomarkers in mTBI Recruiting NCT03221751 Phase 4 prazosin hydrochloride;placebo
42 Prazosin for Post-Concussive Headaches Recruiting NCT02965027 Phase 4 Prazosin;Placebos
43 Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits in Children Active, not recruiting NCT02712996 Phase 4 Lisdexamfetamine;Placebo
44 Citicholine-Amantadine Trial in Traumatic Brain Injury Active, not recruiting NCT03430817 Phase 4 Citicholine;Amantadine
45 Quality Improvement and Practice Based Research in Neurology Using the EMR Enrolling by invitation NCT02670161 Phase 4 Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
46 Timing of VTE Prophylaxis in TBI Suspended NCT03081169 Phase 4 Enoxaparin Sodium 150 MG/ML Prefilled Syringe;Heparin
47 Effect of Namenda on Short Term Memory and Attention in Patients With Mild to Moderate Traumatic Brain Injury Terminated NCT00462228 Phase 4 Memantine;Placebo
48 A Comparison of Propofol Versus Midazolam to Sedate Critically Brain Injury; Measurement of Cytokine Response and Assessment of Function Terminated NCT01712477 Phase 4 Intravenous sedation using propofol;Intravenous sedation with midazolam
49 Treatment Of Adult Growth Hormone Deficiency After Traumatic Brain Injury Terminated NCT00555009 Phase 4 Genotropin;Placebo
50 Neuropsychological Effects of Hydrocortisone in Patients With Partial Adrenal Insufficiency Terminated NCT01089075 Phase 4 Hydrocortisone;Placebo

Search NIH Clinical Center for Traumatic Brain Injury

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Traumatic Brain Injury cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Traumatic Brain Injury:
MultiStem, bone marrow-derived cells for neurological disorders
Embryonic/Adult Cultured Cells Related to Traumatic Brain Injury:
Bone marrow-derived adherent progenitor cells (MultiStem) PMIDs: 23205020 20637752 23020860 21175285 21248119

Genetic Tests for Traumatic Brain Injury

Anatomical Context for Traumatic Brain Injury

MalaCards organs/tissues related to Traumatic Brain Injury:

42
Brain, Testes, Eye, Pituitary, Spinal Cord, Endothelial, Pons
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Traumatic Brain Injury:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate

Publications for Traumatic Brain Injury

Articles related to Traumatic Brain Injury:

(show top 50) (show all 5145)
# Title Authors Year
1
Interactive Effect of Traumatic Brain Injury and Psychiatric Symptoms on Cognition among Late Middle-Aged Men: Findings from the Vietnam Era Twin Study of Aging. ( 29978738 )
2019
2
Alcohol dependence treating agent, acamprosate, prevents traumatic brain injury-induced neuron death through vesicular zinc depletion. ( 30731068 )
2019
3
Memantine: From Alzheimer Disease to Traumatic Brain Injury. ( 30471450 )
2019
4
Psychometric Evaluation of Anxiety, Depression, and Sleep Quality after a Mild Traumatic Brain Injury: A Longitudinal Study. ( 31110595 )
2019
5
Quercetin mitigates anxiety-like behavior and normalizes hypothalamus-pituitary-adrenal axis function in a mouse model of mild traumatic brain injury. ( 30882424 )
2019
6
The blockade of corticotropin-releasing factor 1 receptor attenuates anxiety-related symptoms and hypothalamus-pituitary-adrenal axis reactivity in mice with mild traumatic brain injury. ( 30883392 )
2019
7
Long-Term Effects of Traumatic Brain Injury on Anxiety-Like Behaviors in Mice: Behavioral and Neural Correlates. ( 30728770 )
2019
8
Risks of bipolar disorder, depressive disorder, and traumatic brain injury among siblings of patients with attention-deficit hyperactivity disorder. ( 30419534 )
2019
9
Polygenic Risk and Neural Substrates of Attention-Deficit/Hyperactivity Disorder Symptoms in Youths With a History of Mild Traumatic Brain Injury. ( 30119875 )
2019
10
Cerebral Edema and Neurological Recovery after Traumatic Brain Injury Are Worsened if Accompanied by a Concomitant Long Bone Fracture. ( 30084745 )
2019
11
Lack of Benefit on Brain Edema, Blood-Brain Barrier Permeability, or Cognitive Outcome in Global Inducible High Mobility Group Box 1 Knockout Mice Despite Tissue Sparing after Experimental Traumatic Brain Injury. ( 30045665 )
2019
12
Deficiency of plasminogen activator inhibitor type 2 limits brain edema formation after traumatic brain injury. ( 30755137 )
2019
13
Dynamic features of brain edema in rat models of traumatic brain injury. ( 30969247 )
2019
14
Handling of missing outcome data in traumatic brain injury research - a systematic review. ( 31062649 )
2019
15
Comparing Composite Scores for the ANAM4 TBI-MIL for Research in Mild Traumatic Brain Injury. ( 31063188 )
2019
16
Prophylactic Hypothermia for Severe Traumatic Brain Injury. ( 31063565 )
2019
17
Prophylactic Hypothermia for Severe Traumatic Brain Injury-Reply. ( 31063568 )
2019
18
Therapeutical effects of chrysin in a rat model of traumatic brain injury: A behavioral, biochemical, and histological evidence. ( 31063733 )
2019
19
Correlation between cerebral co-oximetry (rSO2) and outcomes in traumatic brain injury cases: A prospective, observational study. ( 31065189 )
2019
20
Post-traumatic Anterior Cerebral Artery Rupture after a Severe Traumatic Brain Injury. ( 31065211 )
2019
21
Hypopituitarism After Traumatic Brain Injury. ( 31065469 )
2019
22
Association of Statewide Implementation of the Prehospital Traumatic Brain Injury Treatment Guidelines With Patient Survival Following Traumatic Brain Injury: The Excellence in Prehospital Injury Care (EPIC) Study. ( 31066879 )
2019
23
Patient-reported auditory handicap measures following mild traumatic brain injury. ( 31066921 )
2019
24
Indirect Traumatic Optic Neuropathy in Mild Chronic Traumatic Brain Injury. ( 31067321 )
2019
25
Altered Mental Status in Children After Traumatic Brain Injury. ( 31067334 )
2019
26
Social rehabilitation for military veterans with traumatic brain injury, psychological trauma, and chronic neuropsychiatric symptoms: Intervention development and initial outcomes. ( 31070444 )
2019
27
In-hospital costs after severe traumatic brain injury: A systematic review and quality assessment. ( 31071199 )
2019
28
Mitochondria-Targeted Antioxidants as Potential Therapy for the Treatment of Traumatic Brain Injury. ( 31071926 )
2019
29
Cathodal Transcranial Direct-Current Stimulation Selectively Decreases Impulsivity after Traumatic Brain Injury in Rats. ( 31072218 )
2019
30
A serum protein biomarker panel improves outcome prediction in human traumatic brain injury. ( 31072225 )
2019
31
Gene expression profile of the hippocampus of rats subjected to traumatic brain injury. ( 31074048 )
2019
32
Transplantation of human meningioma stem cells loaded on a self-assembling peptide nanoscaffold containing IKVAV improves traumatic brain injury in rats. ( 31075516 )
2019
33
A systematic review of cross-sectional differences and longitudinal changes to the morphometry of the brain following paediatric traumatic brain injury. ( 31075554 )
2019
34
BpV(pic) confers neuroprotection by inhibiting M1 microglial polarization and MCP-1 expression in rat traumatic brain injury. ( 31075560 )
2019
35
Artifact removal from neurophysiological signals: impact on intracranial and arterial pressure monitoring in traumatic brain injury. ( 31075774 )
2019
36
A traumatic brain injury prognostic model to support in-hospital triage in a low-income country: a machine learning-based approach. ( 31075779 )
2019
37
Screening the expression of several miRNAs from TaqMan Low Density Array in traumatic brain injury: miR-219a-5p regulates neuronal apoptosis by modulating CCNA2 and CACUL1. ( 31077370 )
2019
38
Family Involvement in Traumatic Brain Injury Inpatient Rehabilitation: A Propensity Score Analysis of Effects on Outcomes During the First Year after Discharge. ( 31077646 )
2019
39
Traumatic brain injury and coextensive psychopathology: New evidence from the 2016 Nationwide Emergency Department Sample (NEDS). ( 31078785 )
2019
40
Sex Differences in Sex Hormone Profiles and Prediction of Consciousness Recovery After Severe Traumatic Brain Injury. ( 31080439 )
2019
41
Time to reconsider extended erythropoietin treatment for infantile traumatic brain injury? ( 31082389 )
2019
42
Intracranial pressure management and neurological outcome for patients with mild traumatic brain injury who required neurosurgical intervention: a Japanese database study. ( 31084363 )
2019
43
Traumatic Brain Injury Results in Dynamic Brain Structure Changes Leading to Acute and Chronic Motor Function Deficits in a Pediatric Piglet Model. ( 31084386 )
2019
44
Controlled cortical impact leads to cognitive and motor function deficits that correspond to cellular pathology in a piglet traumatic brain injury model. ( 31084390 )
2019
45
A Systematic Review and Meta-Analysis on the Association Between Driving Ability and Neuropsychological Test Performances after Moderate to Severe Traumatic Brain Injury. ( 31084639 )
2019
46
Cognitive rehabilitation post traumatic brain injury: A systematic review for emerging use of virtual reality technology. ( 31085075 )
2019
47
Efficacy and safety of intrathecal meropenem and vancomycin in the treatment of postoperative intracranial infection in patients with severe traumatic brain injury. ( 31086592 )
2019
48
Remodeling dendritic spines for treatment of traumatic brain injury. ( 31089035 )
2019
49
Acute drivers of neuroinflammation in traumatic brain injury. ( 31089036 )
2019
50
Traumatic axonal injury of the cingulum in patients with mild traumatic brain injury: a diffusion tensor tractography study. ( 31089054 )
2019

Variations for Traumatic Brain Injury

Expression for Traumatic Brain Injury

Search GEO for disease gene expression data for Traumatic Brain Injury.

Pathways for Traumatic Brain Injury

Pathways related to Traumatic Brain Injury according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.13 BDNF CASP3 GH1 IGF1 IL10 IL6
2
Show member pathways
13.1 AQP4 BDNF CASP3 GH1 IGF1 IL6
3
Show member pathways
12.82 BDNF CASP3 GH1 IGF1 IL6
4
Show member pathways
12.2 GFAP GH1 IL10 IL6
5
Show member pathways
12.04 BDNF GH1 IGF1 IL10 IL6
6 12.03 APOE COMT ENO2 GFAP MBP S100B
7
Show member pathways
11.87 BDNF GH1 IGF1 IL10 IL6
8 11.87 AQP4 BDNF CASP3 IL10 IL6
9 11.72 ENO2 IGF1 IL6
10 11.68 CASP3 IL10 IL6
11 11.57 CASP3 IL10 IL6
12 11.57 BDNF GFAP IGF1 S100B
13 11.55 BDNF GH1 IGF1 IL6
14 11.47 BDNF IGF1 IL10 IL6
15 11.38 CASP3 IL6 UCHL1
16 11.31 APOE IGF1 IL6
17 11.18 AQP4 BDNF CASP3 GFAP IL6 MBP
18 11.11 BDNF DRD2 IGF1 IL10
19 10.78 BDNF GFAP GH1 IGF1 IL10 IL6
20 10.71 BDNF CASP3

GO Terms for Traumatic Brain Injury

Cellular components related to Traumatic Brain Injury according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 APOE BDNF GH1 IGF1 IL10 IL6
2 extracellular space GO:0005615 9.76 APOE BDNF ENO2 GH1 IGF1 IL10
3 neuronal cell body GO:0043025 9.1 APOE CASP3 ENO2 MBP S100B UCHL1
4 myelin sheath GO:0043209 8.65 MBP

Biological processes related to Traumatic Brain Injury according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.76 CASP3 COMT DRD2 IL10
2 axonogenesis GO:0007409 9.58 DRD2 S100B UCHL1
3 regulation of signaling receptor activity GO:0010469 9.55 BDNF GH1 IGF1 IL10 IL6
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.54 GH1 IGF1 IL6
5 positive regulation of glial cell proliferation GO:0060252 9.51 GFAP IL6
6 negative regulation of B cell proliferation GO:0030889 9.49 CASP3 IL10
7 dopamine metabolic process GO:0042417 9.48 COMT DRD2
8 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.43 GH1 IGF1
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.43 GH1 IGF1 IL6
10 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.32 IL10 MBP
11 response to inactivity GO:0014854 8.96 DRD2 IL10
12 response to glucocorticoid GO:0051384 8.92 CASP3 IL10 IL6 S100B

Molecular functions related to Traumatic Brain Injury according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.83 APOE AQP4 CASP3 COMT DRD2 ENO2
2 tau protein binding GO:0048156 9.16 APOE S100B
3 growth factor activity GO:0008083 9.02 BDNF GH1 IGF1 IL10 IL6

Sources for Traumatic Brain Injury

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
25